Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan

This license will enable Abbott to enhance access to this novel therapy to more patients across India

Alkem signs license agreement with Takeda to commercialise Vonoprazan in India

Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)

Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure

Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%

Zydus signs patent licensing agreement with Takeda for 'VaultA’ in India

The pooled prevalence of GERD in the Indian population is 15.6 %

Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan

Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India

Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders

Torrent inks licensing agreement with Takeda to commercialize its novel gastrointestinal drug in India

Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders

Zydus Wellness launches pilot for ready-to-drink beverage Glucon-D Activors

The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness

IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24

The company recently received CEP certificate approval for Losartan Potassium by EDQM

AstraZeneca discontinues Phase III trials of Stabilizer-CKD and Dialize-Outcomes

STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme